Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First in Human Study of NNC0705-0002 in Healthy Adults
NCT07797855Phase 1Recruiting
- Sponsor
- Novo Nordisk
- Start
- Sep 2026
- Primary completion
- Aug 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in cardiometabolic diseases comparing NNC0705-0002 with Placebo (2 arms). Primary endpoints: Number of treatment emergent adverse events at Day 13, Area under the plasma concentration-time curve from time 0 to last measurable concentration at Day 15 and 1 more. Started Sep 2026; status: recruiting.
02
Drugs
NNC0705-0002
03
Conditions
cardiometabolic diseases
Beyond the preview
Go deeper on NCT07797855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07797855.